Last reviewed · How we verify

Litfulo — Competitive Intelligence Brief

Litfulo (ritlecitinib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Dermatology.

marketed Tyrosine-protein kinase ITK/TSK Dermatology Live · refreshed every 30 min

Target snapshot

Litfulo (ritlecitinib) — Pfizer. Litfulo works by blocking the activity of a specific enzyme called tyrosine-protein kinase ITK/TSK.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Litfulo TARGET ritlecitinib Pfizer marketed Tyrosine-protein kinase ITK/TSK 2023-01-01
Litfulo pf-06651600 Pfizer marketed Tyrosine-protein kinase ITK/TSK 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Litfulo — Competitive Intelligence Brief. https://druglandscape.com/ci/ritlecitinib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: